Global Anti-Infective Drugs Market is segmented By Product Type (Antibiotics, Antivirals, Antifungals, Others), By Indication (HIV Infection, Pneumonia, Respiratory Virus Infection, Sepsis, Tuberculosis, Other Indications), By Distribution Channel (Hospital Pharmacy, Pharmacy Stores, Other), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Anti-Infective Drugs Market Overview
The Global "Anti-Infective Drugs Market" is estimated to reach at a high CAGR during the forecast period (2024-2031).
Anti-infective drugs are substances that prevent infectious agents or organisms from spreading. These are mostly communicable diseases spread from viruses, bacteria, fungi, and other organisms. Infections thus caused can be classified depending on the type of organism causing infection and the symptoms and medical signs shown by the host.
Anti-Infective Drugs Market Summary
|
Metrics |
Details |
|
Market CAGR |
high |
|
Segments Covered |
By Product Type, By Indication,By Distribution Channel and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
For More Insights Request Free Sample
Anti-Infective Drugs Market Dynamics
The global anti-infective drugs market growth is driven by the rising awareness among the population about various infectious diseases and the availability of reimbursements to infection treatment in various countries have played a significant role in driving the market. The rise in the number of hospitals and primary care clinics drives the demand for anti-infective drugs.
The increasing number of companies in the market is expected to drive the growth in the forecast period
Anti-infective drugs have been one of the major segments for many pharmaceutical companies for decades. Over the past two decades, the infection rate has grown significantly, particularly across low and middle-income countries. There are a large number of companies well-established in the market with their products in the form of antifungals, antibiotics, anti-bacterial, anti-protozoans and antivirals targeting cytochrome, interleukin, interferons and some are multi-drug resistants. The primary driving factor for the growth of the market is the increasing burden of several infectious diseases across developed and emerging markets such as different forms of influenza, diarrhea, hepatitis, and urinary tract infections, among others, which need more attention from pharmaceutical and biotechnology companies.
Increase in hyperlipidemia cases expected to drive the market growth
Factors like the increasing prevalence of infectious diseases and antimicrobial resistance to existing anti-infective agents are estimated to fuel the market growth. Moreover, escalating health consciousness, about the availability of diagnostics for infectious diseases, and avoidable risks associated with the early diagnosis, are some of the factors projected to boost the growth.
Companies have recently launched a panel of FDA-approved, modified antibiotics for their use in the treatment of acute bacterial skin and soft tissue infections; these drugs include Dalvance (Dalbavancin), Orbactiv (Oritavancin), Sivextro (Tedizolid), and Zevtera (Ceftobiprole). The high penetration of these anti-infective drugs due to their increased efficacy is expected to serve as a growth driver for the anti-infective agents market in the forecast period.
For instance, in 2016, the Food and Drug Administration (FDA) approved drugs, such as Descovy by Gilead, for the treatment of HIV-1 infection and Zepatier by Merck that targets chronic Hepatitis C virus (HCV) genotypes 1 or 4 infections in adults.
High investment costs in R&D is likely to hinder the market growth
However, some of the major restraints to this market are high investment costs in R&D, as major importance is given to multi-drug resistant drugs, where several companies' products fail in the early-stage or clinical stage of development. Also, the shortage of resources in healthcare facilities particularly in emerging markets restricts the growth of this market.
COVID-19 Impact Analysis
COVID-19 was may have a complex long-term impact on anti-infective resistance. Coordinated strategies at the individual, health-care and policy levels are urgently required to inform necessary actions to reduce the potential longer-term impact on anti-infective and on access to effective antimicrobials. However, the impact of covid-19 on the pharmaceutical industry is projected to be neutralized by certain factors including higher demand for currently marketed drugs including anti-infective.
Anti-Infective Drugs Market Segment Analysis
The antiviral segment is expected to grow at the fastest CAGR during the forecast period (2024-2031)
The antiviral agents are expected to show high growth over the forecast period, as several drug manufacturers are exploring opportunities to expand in the lower and middle-income countries, where the epidemic infection rate is high. There is high diversity in the patient pool which requires long treatment procedures in hospital facilities as well as home care treatments.
Antiviral drugs refer to those prescription medicines that are capable of fighting against flu viruses in one’s body. Antiviral drugs could include intravenous solutions, inhaled powder, liquid, or pills. However, antiviral drugs cannot be purchased just over-the-counter, one would need a prescription for obtaining such drugs. The global antiviral drugs market is likely to observe considerable growth due to the rising incidences of viral infections.
Moreover, there has been observed a growing interest by government in countries showing fast economic growth, to collaborate with hospitals and global pharmaceutical companies to improve the distribution rate of antiviral agents to the needful in the required area of a country. Such factors are expected to boost the growth of the antivirals segment over the forecast period.
The hospital pharmacy is expected to dominate the Anti-Infective drugs market during the forecast period
The hospital pharmacies held the largest share in the Anti-Infective drugs market. This is mainly owing to the increasing number of patients suffering from conditions that are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, the growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment.
Geographical Share
North America region holds the largest market share global Anti-Infective drugs market
North America region is dominating the global anti-infective drugs market accounted for the largest market share in 2020. The presence of sophisticated healthcare infrastructure and high awareness among end-users such as clinicians and healthcare professionals are estimated to be the key growth drivers. Moreover, high purchasing power for expensive drugs and the presence of favourable reimbursement policies are anticipated to further fuel the regional market during the forecast period.
Competitive Landscape
The anti-infective drugs market is moderately competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Abbott Laboratories Limited, Cipla Ltd., Claris Life Sciences Ltd., Glenmark Pharmaceuticals Ltd., GlaxoSmithKline Pharmaceuticals Ltd., Lupin Ltd., Panacea Biotech Ltd., Novartis AG, Pfizer Ltd., Ranbaxy Laboratories Ltd., and Sun Pharmaceutical Industries Ltd. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the anti-infective drugs market globally.
Anti-Infective Drugs Market Key Companies to Watch
Glenmark Pharmaceuticals Limited
Overview: Glenmark Pharmaceuticals Limited is a global pharmaceutical company. The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, the United States, Latin America, Europe, and the Rest of the World (ROW). It has approximately seven molecules, over two NCEs, and approximately five NBEs in various stages of pre-clinical and clinical development. It is focused on developing and marketing branded and generic formulations. It focuses on manufacturing products across therapeutic areas of dermatology, respiratory, and oncology. Its active pharmaceuticals ingredients (API) business spans over 80 countries, including regulated markets of the United States, Europe, Japan, and Canada. Its products are primarily marketed in the United States and Western Europe. It has offices in over 40 countries and operates approximately 20 manufacturing facilities in over five countries. It operates over five research and development (R&D) centers.
Product Portfolio: The Company’s portfolio comprised 164 products including API business, an independent subsidiary called Glenmark Life Sciences, Glenmark Pharmaceuticals is focused on the areas of respiratory and dermatology.
The global Anti-Infective drugs market report would provide an access to an approx. 61 market data table, 56 figures, and 180 pages.
